Croatia, Pharma and Corruption - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Croatia, Pharma and Corruption
Croatia is on track to join the EU in 2013 and offers a well-developed pharmaceutical market. However, its EU membership application has undergone much scrutiny because of concerns regarding corruption, organised crime and counterfeit pharmaceuticals.

Pharmaceutical Technology Europe
Volume 23, Issue 8


1. BBC News, "Croatia cleared for EU membership in 2013" (UK, 2011)., accessed 30 June 2011.

2. Business Monitor, Croatia Pharmaceuticals and Healthcare Report Q3 (UK, May 2011).

3. ANZAG, "ANZAG: Result under pressure" press release (Germany, 2011), accessed 30 June 2011.

4. Epsicom, The Outlook for Pharmaceuticals in Central & Eastern Europe (UK, April 2011).

5. L. Voncina and T. Strizrep, Eurohealth 16 (4), 20–22 (2011).

6. L. Voncina "Croatian 2009–2010 pharma reform", Ekonom:east Media Group, online (Serbia, 2011),, accessed 30 June 2011.

7. FarmaVita.Net, "Croatia — Pharmaceuticals and Biotechnology" (2011),, accessed 29 June 2011.

8. Pliva, "Pliva: History" (Croatia),, accessed 30 June 2011.

9. The Guardian, "US embassy cables: Allegations over Croatian pharmaceutical company deal rebutted" (UK, 2010), accessed 30 June 2011.

10. PETO EVIC, "Croatia Fights Counterfeiting" (Belgium, 2011)., accessed 30 June 2011.

11. Securing Pharma, "Croatian study uncovers counterfeit medicines" (2010), accessed 29 June 2011.

12. V. Stecher et al., 12th Congress of the European Society for Sexual Medicine (Lyon, France, 2009).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here